Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
06/2003
06/05/2003WO2003045944A1 Aromatic sulfone hydroxamic acids and their use as protease inhibitors
06/05/2003WO2003045930A1 Therapeutic compounds
06/05/2003WO2003045926A1 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
06/05/2003WO2003045920A1 4-aminoquinoline compounds
06/05/2003WO2003045582A1 Metallic structures incorporating bioactive materials and methods for creating the same
06/05/2003WO2003045404A2 Treatment and diagnosis of diseases associated with adverse levels of zinc, cadmium and calcium
06/05/2003WO2003045379A1 Hydrazonopyrazole derivatives and their use as therapeutics
06/05/2003WO2003045371A1 Pharmaceutical compositions and methods for administering ep2 receptor selective agonists
06/05/2003WO2003045363A2 Treatment of th2 dominated immunological disease states with progesterone receptor antagonists
06/05/2003WO2003045362A2 Treatment of th1 dominated immunological disease states with non-endogenous gestagen compounds
06/05/2003WO2003045351A1 Controlled release polymeric compositions of bone growth promoting compounds
06/05/2003WO2003045333A2 Treatment of hyperproliferative diseases using active vitamin d analogues
06/05/2003WO2003045331A2 Formulations for oral administration of cromolyn sodium
06/05/2003WO2003045318A2 Manipulation of cytokine levels using cd83 gene products
06/05/2003WO2003045316A2 Polynucleotide therapy
06/05/2003WO2003045313A2 2-aminoquinoline compounds
06/05/2003WO2003045228A2 Methods for treating autoimmune disorders, and reagents related thereto
06/05/2003WO2003045136A1 Disruption of the prostaglandin e synthase 2 gene
06/05/2003WO2002081007A3 Methods of isolating blood components using a centrifuge and uses thereof
06/05/2003WO2002074924A3 Method for measuring serine palmitoyltransferase in mammalian tissue and use thereof
06/05/2003WO2002031514A3 A method of determining the initial dose of vitamin d compounds
06/05/2003US20030106085 Disruption of the prostaglandin E synthase 2 gene
06/05/2003US20030105333 RXR activating molecules
06/05/2003US20030105318 G-protein transmembrane domain; protein synthesis inhibitor; neurotransmitter
06/05/2003US20030105161 Analgesics; antiinflamamtory agents
06/05/2003US20030105159 Kavalactone compositions and methods of use
06/05/2003US20030105151 Anticancer agents; antiinflammatory agents; autoimmune diseases; rheumatic diseases
06/05/2003US20030105150 Method of treating of demyelinating diseases or conditions
06/05/2003US20030105148 Selective estrogen receptor modulators
06/05/2003US20030105142 Amide derivatives useful as inhibitors of the production of cytokines
06/05/2003US20030105123 For therapy of respiratory system disorders
06/05/2003US20030105118 Tricyclic quinazolinediones
06/05/2003US20030105115 For therapy of cancer, diseases mediated by kinase, osteoporosis
06/05/2003US20030105110 Novel compounds
06/05/2003US20030105092 Prevention of loss and restoration of bone mass by certain prostaglandin agonists
06/05/2003US20030105090 For therapy of cancer, diabetes
06/05/2003US20030105084 Compound which inhibit the release of inflammatory cytokines
06/05/2003US20030105080 Thienylalanine derivatives as inhibitors of cell adhesion
06/05/2003US20030105069 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
06/05/2003US20030105050 Disorders caused by overproduction of collagen fibres, for example, liver cirrhosis, kidney, liver and heart fibrosis, scleroderma, hypertrophic scars and keloids
06/05/2003US20030105031 Administering therapeutically effective amount of one or more flavonoids and carrier for therapy of reactive and inflammatory dermatoses
06/05/2003US20030105027 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
06/05/2003US20030104992 A cyclic polypeptides; immunosuppressive anti-inflammatory activity, inhibiting antigen-induced inflammatory cell infiltration
06/05/2003US20030104977 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
06/05/2003US20030104975 Useful for identification of compounds that induce or inhibit the recruitment of the p160 family cofactors, especially TIF-2 and/ or SRCs cofactors (Translation initiation factor-2 and steroid receptor cofactors)
06/05/2003US20030104974 Dual inhibitorsof PDE 7 and PDE 4
06/05/2003US20030104532 Neuroprotectants; angoigenesis inhibitors; transcription factors
06/05/2003US20030104485 Antibodies specific for osteoprotegerin binding proteins and method of use
06/05/2003US20030104406 Modified and stabilized GDF propeptides and uses thereof
06/05/2003US20030104400 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of infammatory, immunol;ogical and nervous system disorders
06/05/2003US20030104088 Sulfated proteoglycan; one or more of a hexosamine sulfate,a flavone, olive kernel extract, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of CRH, caffeine, and a polyamine.
06/05/2003US20030104087 Proteoglycan compositions for treating arthritic inflammatory conditions
06/05/2003US20030104031 Controlled release polymeric compositions of bone growth promoting compounds
06/05/2003US20030104010 Novel, non-antigenic, mucosal adjuvant formulation which modulates the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
06/05/2003US20030103978 Antibodies and antigen binding domains used to prevent or treat conditions relating to loss of bone mass and bone disorders; nucleic acid encoding antibodies and antigen binding domains
06/05/2003US20030103973 Method for reducing tumor growth with VEGF antagonists combined with radiation and chemotherapy
06/05/2003US20030103954 Comprises vitamin D3 for regulating cell differentiation and/or cell proliferation
06/05/2003US20030103953 Comprises vitamin D3 for controlling cell differentiation and/or cell proliferation
06/05/2003US20030103942 Comprises recombinant adeno-associated virus vectors encoding TNF antagonist; antiinflammatory agents for connective tissues and joints
06/05/2003CA2468494A1 Pharmaceutical compositions and methods for administering ep2 receptor selective agonists
06/05/2003CA2468184A1 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
06/05/2003CA2468159A1 4-aminoquinoline compounds
06/05/2003CA2468154A1 Methods for regulating levels of zinc, cadmium and calcium in humans and for diagnosing, or screening for the risk of developing, diseases associated with abnormal levels of cadmium, zinc and calcium in body fluids and tissues
06/05/2003CA2468131A1 Disruption of the prostaglandin e synthase 2 gene
06/05/2003CA2468071A1 Triazolo[4,3-a]pyrido[2,3-d]pyrimidin-5-one derivatives, compositions containing same, preparation method and use thereof
06/05/2003CA2468020A1 Osteopontin-related compositions and methods
06/05/2003CA2468015A1 2-aminoquinoline compounds
06/05/2003CA2467892A1 Methods and compositions for derepression of iap-inhibited caspase
06/05/2003CA2467565A1 Aromatic sulfone hydroxamic acids and their use as protease inhibitors
06/05/2003CA2466870A1 Methods for treating autoimmune disorders, and reagents related thereto
06/05/2003CA2466867A1 Treatment of hyperproliferative diseases using active vitamin d analogues
06/05/2003CA2466863A1 Formulations for oral administration of cromolyn sodium
06/05/2003CA2466845A1 Manipulation of cytokine levels using cd83 gene products
06/05/2003CA2435758A1 Polynucleotide therapy_against autoantigens for treating insulin dependent diabetes mellitus
06/04/2003EP1316547A1 Novel crystals of n-hydroxy-2(s)-methyl-5-ethoxymethoxy -4(s)- n-(4-phenoxyphenylcarbonyl)amino]pentanamide, process for their production and medicines containing the crystals as the active ingredient
06/04/2003EP1315965A2 Methods and compositions for in vitro targeting
06/04/2003EP1315840A2 Biopanning and rapid analysis of selective interactive ligands (brasil)
06/04/2003EP1315830A2 Compositions and methods for targeting peptides in humans in vivo
06/04/2003EP1315812A2 Modified polypeptides stabilized in a desired conformation and methods for producing same
06/04/2003EP1315804A2 Novel mmp-2 derivatives for use as inhibitors of integrin alpha vbeta 3
06/04/2003EP1315800A2 Human proteases
06/04/2003EP1315758A2 Methods and reagents for protease inhibition
06/04/2003EP1315735A1 Phosphate derivatives as immunoregulatory agents
06/04/2003EP1315727A2 7-oxo pyridopyrimidines
06/04/2003EP1315726A1 7- oxo pyridopyrimidines as inhibitors of cellular proliferation
06/04/2003EP1315694A2 Inhibitors of alpha 4 mediated cell adhesion
06/04/2003EP1315513A2 "pseudo"-native chemical ligation
06/04/2003EP1315512A2 Adenoviral targeting and manipulation of immune system response using targeting peptides
06/04/2003EP1315511A2 Synthetic erythropoiesis stimulating proteins
06/04/2003EP1315504A1 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
06/04/2003EP1315502A1 Method for treating erectile dysfunction and increasing libido in men
06/04/2003EP1315501A1 Alpha v integrin receptor antagonists
06/04/2003EP1315496A2 The treatment of inflammatory disorders
06/04/2003EP1315482A2 Water-dispersible encapsulated sterols
06/04/2003EP1315476A2 Nitric oxide-producing hydrogel materials
06/04/2003EP1315475A1 Lung surfactant compositions with dynamic swelling behaviour
06/04/2003EP1252150B1 Heterocyclic derivatives, preparation method and pharmaceutical compositions containing same
06/04/2003EP1155014B1 New benzimidazole compounds for use as active therapeutic substances, process for the preparation of these compoudns and pharmaceutical compositions comprising them
06/04/2003EP1075476B1 Novel benzimidazoles and benzoxazoles
06/04/2003EP0973790B1 Estra-5(10),7-dienes with estrogenic activity
1 ... 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 ... 820